The board of directors of the Company has, based on the authorization from the general meeting on 23 May 2024, resolved on a directed share issue of a total of 130,443 shares to those who acted as guarantors in connection with the exercise of warrants of series TO 4 (the "Directed Issue"), of which 88,078 shares relate to the utilization of the so-called top guarantee and 42,365 shares relate to remuneration to the guarantors (all guarantors have chosen to have the guarantee compensation paid in shares). The shares relating to remuneration to the guarantors will be paid by set-off of the guarantors' respective claims against the Company. In total, the guarantors' claims amount to approximately SEK 252,495.

The subscription price in the Directed Issue corresponds to the exercise price for the warrants of series TO 4, i.e. SEK 5.96 per share, in accordance with the guarantee agreements entered into. The terms of the agreement were determined through arm's length negotiations with the guarantors and with the help of financial advisors. Hence, the Company considers the terms to be in line with market terms.

The reason for deviating from the shareholders' preferential rights is to fulfil agreements entered into between the Company and the subscribers (which have previously been announced), who have acted as guarantors in connection with the exercise of warrants of series TO 4.

The Directed Share Issue entails that the Company's share capital will increase by a maximum of SEK 13,044.30, from SEK 670,477 to SEK 683,521.3, and that the number of shares will increase by a maximum of 130,443 shares, from 6,704,770 shares to 6,835,213 shares. The dilution resulting from the Directed Issue amounts to approximately 1.9 percent.

Advisors

In connection with the exercise of warrants of series TO 4, Prostatype has engaged Gemstone Capital ApS as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the Company, please contact:

Fredrik Rickman, VD
Tel: +46 (0)73-049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Certified Adviser

Carnegie Investment Bank AB (publ), +46 73 856 42 65, certifiedadviser@carnegie.se